Obesity has escalated into a global epidemic, with over 1 billion individuals affected worldwide, including nearly 880 million adults and 159 million children and adolescents aged 5–19 years (World Obesity Federation). This surge in obesity rates is closely linked to a heightened risk of chronic diseases such as type 2 diabetes, cardiovascular diseases, and certain cancers.

The Molecular Targets Driving the Revolution

Modern incretin-based therapies harness three key hormone receptors that work together to regulate glucose metabolism, appetite, and energy balance:GLP-1R (Glucagon-Like Peptide-1 Receptor) – Activated by drugs such as Semaglutide, this receptor stimulates insulin secretion, slows gastric emptying, and promotes satiety, helping reduce food intake and improve blood glucose control. GIPR (Glucose-Dependent Insulinotropic Polypeptide Receptor) – Acts synergistically with GLP-1R in dual agonists like Tirzepatide, enhancing insulin sensitivity and fat metabolism for greater metabolic benefits. GCGR (Glucagon Receptor) – When co-activated with GLP-1R and GIPR in triple agonists such as Retatrutide, it boosts energy expenditure and fat oxidation, accelerating weight reduction.

These three receptor pathways form the foundation of next-generation multi-agonist therapies that deliver deeper, more sustained weight-loss and metabolic improvements than single-target drugs.

Semaglutide is the most important receptor agonist of GLP-1 and has 94% sequence homology with human GLP-1. In the clinical treatment of diseases, GLP-1 receptor can be activated to stimulate the secretion of human insulin. Therefore, in the clinical treatment of type 2 diabetes, the GLP-1 receptor agonist Semaglutide is a scientific therapeutic agent. At present, it is generally believed that the long-term mechanism of Semaglutide is based on the modification of its structure. Among them, aminoisobutyric acid can have an ideal effect of increasing stability and avoiding the occurrence of drug degradation. Compared with traditional drugs, the drug can form a stable combination with albumin, so it can ensure the molecular weight of the drug and prolong the half-life of the drug in the human body.

The main metabolic pathway of Semaglutide is fatty acid side chain β-  Oxidation will be eliminated with human excreta, but some drug prototypes will still be eliminated with the urine of patients. In addition, Semaglutide tirzepatide and retatrutide has ideal safety and tolerability characteristics. After medication, the most common adverse reaction of patients is gastrointestinal reaction, and most of the symptoms will naturally relieve, so it has the advantage of medication safety.

       Global Market Scale Surges, Supply Chain Guarantee Becomes Key

According to data from market research institutions, the global weight loss peptide market scale has exceeded 10 billion US dollars, and it is expected to maintain an annual growth rate of more than 25% in the next five years. North America, Europe and the Asia-Pacific region are the main growth markets. With the improvement of people's health awareness and the continuous popularization of weight loss peptides in clinical applications, the market demand for high-quality weight loss peptide raw materials will continue to be strong.

Facing the huge market demand, the stability of the supply chain and the controllability of product quality have become the core of enterprise competition. Relying on years of experience in fine chemical supply chain management, our company has established in-depth cooperation with high-quality production bases around the world to achieve large-scale procurement and stable supply of raw materials; in the production link, we have established a full-process quality control system, equipped with a professional testing team and precision equipment, to ensure that the purity, activity and safety of each batch of weight loss peptide products meet international standards; in terms of service, we have an experienced technical and business team, which can provide customized supply solutions according to customer needs and quickly respond to customers' quotation and technical consultation needs.

Our weight loss peptide product matrix covers a variety of popular and new products. In addition to the aforementioned Semaglutide and Tirzepatide, we can also provide exclusive product solutions according to customers' specific needs. Customers with needs are welcome to communicate with us further to obtain accurate quotations and detailed product information.

关键词：GLP-1 GLP-1R、GIPR和GCGR，Semaglutide，Tirzepatide

Retatrutide ，acid，glucose metabolism,weight loss peptide